Gallium-induced cell death in lymphoma: Role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition

Molecular Cancer Therapeutics

Volumn 5, Issue 11, 2006, Pages 2834-2843

  Chitambar, Christopher R ^a   Wereley, Janine P ^a   Matsuyama, Shigemi ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; CASPASE; CASPASE INHIBITOR; CYTOCHROME C; GALLIUM CITRATE GA 67; GALLIUM NITRATE; INHIBITOR PROTEIN; IRON; IRON 59; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL XL; TRANSFERRIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG SENSITIVITY; DRUG UPTAKE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IRON TRANSPORT; LYMPHOMA; LYMPHOMA CELL; LYMPHOMA CELL LINE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION; PROTEIN TARGETING; STRAIN DIFFERENCE;

ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL DEATH; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; GALLIUM; HUMANS; IRON; JURKAT CELLS; LYMPHOMA, NON-HODGKIN; MITOCHONDRIA; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, TRANSFERRIN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 33845208145     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0285     Document Type: Article

References (46)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Adamson RH, Canellos GP, Sieber SM. Studies on the antitumor activity of gallium nitrate (NSC-I5200) and other group IIIa metal salts. Cancer Chernother Rep 1975;59:599-610.
3. Weick JK, Stephens RL, Baker LH, Jones SE. Gallium nitrate in malignant lymphoma: a Southwest Oncology Group Study. Cancer Treat Rep 1983;67:823-5.
4. Warrell RP, Jr., Coonley CJ, Straus DJ, Young CW. Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 1983;51: 1982-7.
5. Keller J, Bartolucci A, Carpenter JT, Jr., Feagler J. Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:1221-3.
6. Chitambar CR, Zahir SA, Ritch PS, Anderson T. Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Am J Clin Oncol 1997;20:173-8.
7. Straus DJ. Gallium nitrate in the treatment of lymphoma. Semin Oncol 2003;30:25-33.
8. Pro B, Bociek RG, Chitambar CR, et al. Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin's lymphoma (NHL). Blood 2004;104:682A.
9. Harris WR, Pecoraro VL. Thermodynamic binding constants for gallium transferrin. Biochemistry 1983;22:292-9.
10. Larson SM, Rasey JS, Allen DR, et al. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 1980;64:41-53.
11. Chitambar CR, Zivkovic Z. Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res 1987;47:3929-34.
12. Habeshaw JA, Lister TA, Stansfeld AG. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1983;1:498-501.
13. Esserman L, Takahashi S, Rojas V, Warkne R, Levy R. An epitope of the transferrin receptor is exposed on the cell surface of high-grade lymphoma but not low-grade human lymphomas. Blood 1989;74: 2718-29.
14. Kiratli PO, Canpinar H, Ruacan S, Kansu E. Correlation of flow cytometric parameters and transferrin receptors with gallium-67 scintigraphic images in lymphoma patients. Nucl Med Commun 2000;21: 925-31.
15. Chitambar CR, Seligman PA. Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J Clin Invest 1986;78:1538-46.
16. Chitambar CR, Matthaeus WG, Antholine WE, Graff K, O'Brien WJ. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 1988;72:1930-6.
17. Chitambar CR, Narasimhan J, Guy J, Sam DS, O'Brien WJ. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 1991;51:6199-201.
18. Narasimhan J, Antholine WE, Chitambar CR. Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem Pharmacol 1992;44:2403-8.
19. Berggren MM, Burns LA, Abraham RT, Powis G. Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. Cancer Res 1993;53:1862-6.
20. Perchellet EM, Ladesich JB, Collery P, Perchellet JP. Microtubule-disrupting effects of gallium chloride in vitro. Anticancer Drugs 1999; 10: 477-88.
21. Haq RU, Wereley JP, Chitambar CR. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol 1995;23: 428-32.
22. Bates GW, Schlabach MR. The reaction of ferric salts with transferrin. J Biol Chem 1973;248:3228-32.
23. Hunter HM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962;194:495-6.
24. Sawada M, Hayes P, Matsuyama S. Cy-toprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol 2003;5:352-7.
25. Yoshida T, Tomioka I, Nagahara T, et al. Bax-inhibiting peptide derived from mouse and rat Ku70. Biochem Biophys Res Commun 2004; 321:961-6.
26. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 2000;6:2492-500.
27. Tucker CA, Babb G, Klasa RJ, et al. Four human t(11;14)(ql3;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res 2006;30:449-57.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immmunol Methods 1983;65:55-63.
29. Lundberg JL, Chitambar CR. Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res 1990;50:6466-70.
30. Scatchard G. The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 1949;51:660-72.
31. Chitambar CR, Wereley JP. Transferrin receptor-dependent and -independent iron transport in gallium-resistant human lymphoid leukemic cells. Blood 1998;91:4686-93.
32. 67 Ga. J Nucl Med 2003; 44:943-6.
33. Kerr JFR, Harmon BV. Definition and incidence of apoptosis: an historical perspective. In: Tomei LD, Cope FO, editors. Current communications in cell and molecular biology, vol. 3. Apoptosis. The molecular basis of cell death. New York: Cold Spring Harbor Laboratory Press; 1991. p. 5-29.
34. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete, and kinetically invariant. Nat Cell Biol 2000;2:156-62.
35. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
36. Towbin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
37. 67 Ga by human leukemic HL60 cells. Cancer Res 1990;50:1484-7.
38. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999;341: 1986-95.
39. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001;92:57-70.
40. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-911.
41. Qin Q, Patil K, Sharma SC. The role of Bax-inhibiting pepticle in retinal ganglion cell apoptosis after optic nerve transection. Neurosci Lett 2004; 372:17-21.
42. Liu Z, Lu H, Shi H, et al. PUMA overexpression induces reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells. Cancer Res 2005;65:1647-54.
43. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A 1997;94: 3668-72.
44. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
45. Davies NP, Rahmanto YS, Chitambar CR, Richardson DR. Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J Pharmacol Exp Ther 2006;317:153-62.
46. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.